Protelos, first in new class of osteoporosis therapies launched today

Protelos (strontium ranelate), the only osteoporosis therapy to simultaneously increase bone formation and decrease bone resorption, was launched today by Servier Laboratories. The first in a new class of osteoporosis therapies called dual action bone agents (DABAs), Protelos is licenced for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and hip fracture.

Recent Blog Post

Study Reveals Higher BMI Puts Adolescents at Risk for Depression 

5th September 2023 – By King’s College London Children between the ages of 12 and 16 with a higher body...

Diversity at TwinsUK: Genevieve

Genevieve joined the department in 2010 and has since gained an extensive knowledge of the TwinsUK data. She is responsible...

Diversity at TwinsUK: Bridget

Bridget is one of our Clinical Research Nurses, part of the clinic team who you’ll see when coming to St...